Miura T
Department of Orthopaedics, Faculty of Medicine, Branch Hospital, Nagoya University, Japan.
J Int Med Res. 1975;3(3):145-52. doi: 10.1177/030006057500300302.
Clinical and laboratory examinations were conducted in order to assess the long-term tolerability of Voltaren, a new anti-inflammatory and analgesic agent. Pre-treatment, repeated on-treatment and after-treatment investigations of haemoglobin, erythrocyte count, total and differential leucocyte count, platelet count, SGOT, SGPT, alkaline phosphatase, total serum proteins and urinary protein and sugar were conducted in 13 patients. The period of treatment with Voltaren was 110 to 559 days. In all these tests, there were no unwanted effects attributable to long-term treatment with Voltaren. Our study would indicate that Voltaren is a safe drug which has no effect on the organs of haemopoiesis, nor on hepatic or renal function, even in long-term therapy. Therefore, Voltaren can be used as an anti-inflammatory and analgesic agent not only in short-term therapy but also in the long-term treatment of chronic diseases.
为评估新型抗炎镇痛药扶他林（Voltaren）的长期耐受性，进行了临床和实验室检查。对13例患者进行了治疗前、治疗期间重复检查以及治疗后的血红蛋白、红细胞计数、白细胞总数及分类计数、血小板计数、谷草转氨酶（SGOT）、谷丙转氨酶（SGPT）、碱性磷酸酶、血清总蛋白、尿蛋白及尿糖检查。扶他林的治疗期为110至559天。在所有这些检查中，未发现因长期使用扶他林而产生的不良影响。我们的研究表明，扶他林是一种安全的药物，即使在长期治疗中，对造血器官、肝功能及肾功能均无影响。因此，扶他林不仅可用于短期治疗，还可用于慢性疾病的长期治疗，作为抗炎镇痛药使用。
